ARCUS BIOSCIENCES INC
RCUSNYSETrading Snapshot
- Day Range
- $25.54 – $25.79
- 52-Week Range
- $12.87 – $31.74
- Volume
- $2.67B
- Avg Volume
- $2.75B
- Shares Outstanding
- 125.8M
- Next Earnings
- Nov 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $247M
- Last Q Revenue
- $41M
- P/E Ratio
- -6.4
- P/S Ratio
- 26.9x
- EPS (TTM)
- $-3.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +17.1%
Why Investors Own RCUS
- ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARCUS BIOSCIENCES INC
RCUS
StockOtter · stockotter.spaceAbout ARCUS BIOSCIENCES INC
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ARCUS BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift RCUS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ARCUS BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.